IGM Biosciences Inc . (NASDAQ:IGMS) stock has tumbled to a 52-week low, reaching a price level of just $1.59 USD. With a ...
Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected]?or ...
IGM Biosciences is laying off 100 workers as it shuts down two research projects, causing the Mountain View company's stock ...
Read Our Latest Research Report on IGMS IGM Biosciences Trading Down 3.3 % IGMS stock opened at $1.77 on Monday. The firm’s 50-day moving average is $7.65 and its two-hundred day moving average ...
Fintel reports that on January 10, 2025, Stifel downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from Buy to Hold. Analyst Price Forecast Suggests 858.18% Upside As of December 23, 2024, ...
Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company discontinued all clinical development of drugs in its autoimmune franchise ...
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are ...
MOUNTAIN VIEW, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company committed to developing and delivering medicines to treat patients with ...
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of IGM Biosciences, Inc. ("IGM Biosciences, Inc.") (NASDAQ:IGMS) ...
Royal Bank of Canada lowered shares of IGM Biosciences (NASDAQ:IGMS – Free Report) from an outperform rating to a sector perform rating in a report released on Friday, MarketBeat.com reports. The ...
Jan. 09, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company committed to developing and delivering medicines to treat patients with autoimmune and inflammatory ...